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In this report we have investigated that the amino acid is most actively 
metabolized in the tumor cells damaged by antitumor agents, and 
discussed imbalanced amino acid procedure to be combined with 
cancer chemotherapy. 
The concentrations of 24 free amino acids in medium and in cells were 
determined in HeLa cells treated with Adriamycin. The free amino 
acids that decreased in the medium but increased in cells were 
glutamine and arginine. From this result, we treated HeLa cells with 
Adriamycin in medium of glutamine-deficiency and obtained a 
marked cytocidal effect. 
It would be difficult to make tumor tissues of glutamine-depletion in 
the whole body. For clinical application, local administration such as 
intraarterial infusion of L-glutamine antagonists combined with 
antitumor agents is expected as a practical administration method.
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not yet been clarified in tumor tissues or tumor cells treated 
with antitumor agents. 
 The author' has previously reported that the cultured 
cancer cells treated with antitumor agents were signifi-
cantly enlarged in size, suggesting abnormal increase in 
intracellular protein. The increase of intracellular protein 
has been observed for 42K, 45K and 270K with Carvocon, 
an antitumor agent, by Maehara et al.') These studies 
suggest the possibility that cancer chemotherapy might 
have induced some changes in the levels of amino acids 
participating in protein synthesis. 
  In this study, the authors have examined the changes of 
free amino acids in HeLa cells treated with Adriamycin 
(ADM) as a fundamental study for amino acid imbalance 
therapy to be combined with cancer chemotherapy.
Introduction 
The recent progress in total parenteral nutrition has facili-
tated the desired combination of amino acids to be admin-
istered, enabling strict nutritional control. With this 
improvement, amino acid imbalance therapy for cancer is 
being reviewed. 
 The first clinical application of amino acid imbalance 
was reported by Allan et al ') in 1965 with phenylalanine 
and tyrosine imbalance. However, the amino acid imbal-
ance state would be intolerable for human body if as potent 
effect of amino acid imbalance as that obtained in animal 
experiments is expected. Efforts are, therefore, being made 
to find a way out in its use as an adjunct to cancer chemo-
therapy. An example of the efforts was methionine- and 
cystine-free amino acid solution reported by Goseki et al.") 
The combination of this solution and chemotherapy was 
effective in the patients of terminal digestive cancer with-
out developing mortal side effects. Clinical studies of 
amino acid imbalance therapy are steadily progressing with 
the aim to potentate antitumor agents. These studies have 
mainly focussed on amino acid imbalance so far. On the 
other hand, changes of concentrations of amino acids have
Materials and Methods 
HeLa cells in logarithmic growth phase were used for this 
experiment. The HeLa cells were grown in monolayer 
culture in CO, incubator in RPMI1640 (GIBCO, LTI) 
medium supplemented with 10% fetal calf serum (FCS). 2 
X 106/10ml of HeLa cells were plated in a 100mm dish 
and allowed to stand in an incubator for 20hr before use. 
The antitumor agent used in this study was ADM (KYO-
WA HAKKO Co., Ltd), which was added to the RPMI1640 
medium in 100mm dish to make the final concentration of 
0.5,ug/ml. After making the antitumor agent contact with 
the culture for 2hr, it was washed twice with PBS, and then 
the culture was replaced by fresh RPMI1640 medium 
supplemented with 10% FCS. 
 After the exchange of medium, changes with time of the 
concentrations of free amino acids in medium up to 72hr 
and the concentrations of free amino acids in cells at 72hr 
were determined. Furthermore, treatment with Colcemide 
at the final concentration of 0.I,ug/ml was performed for 
24hr to analyze free amino acids in cells of M phase. The 
floating cells were harvested to use for the sample in 
determination of free amino acids in M phase cells. 
 Growth curves of HeLa cells treated with ADM were
compared in RPM11640 medium and RPM11640 medium 
of glutamine-deficiency (NIKKEN Biomedical Laboratory 
Co., Ltd). 
 The medium on HeLa cells treated and not treated with 
ADM were deproteinized with 2.5% sulfosalicylic acid at 
0, 6, 12, 24 and 72hr of culture, and the supernatant after 
centrifugation at 1000rpm was used as the sample for 
analysis of free amino acids in medium. For the determi-
nation of free amino acids in cells, HeLa cells treated and 
not treated with ADM were harvested with 0.12% Trypsin 
and 0.01% EDTA at 72hr of culture. Thus obtained single 
cells were centrifugally precipitated and washed with PBS. 
The pellet was deproteinized with 2.5% sulfosalicylic acid 
and sonicated. It was further centrifuged for 15min at 
3000rpm, and the supernatant was filtered to use for the 
analysis of free amino acid. 
  Twenty-four amino acids were determined in samples of 
500,ag/ml each by ion exchange chromatography and 
ninhydrin reaction with a high performance amino acid 
analyzer (HITACHI 835, Type 50).
Results 
1) Free Amino Acids in Medium 
Concentrations of the 24 amino acids changed virtually in 
the same pattern in groups treated and not treated with 
ADM up to 72hr, though a slight difference was observed 
between the two groups at 6hr. Among the 24 amino acids, 
proline (PRO), alanine (ALA), ornithine (ORN) and glu-
tamic acid (GLU) increased with time, and taurine (TAU), 
asparaginic asid (ASP) and glycine (GLY), showed no 
change in concentration, whereas threonine (THE), serine 
(SER), asparagine (ASN), glutamine (GLN), isoleucine 
(ILE), citrulline (CIT), cystine (CYS), methionine (MET), 
leucine (LEU), tyrosine (TYR), phenylalanine (PHE), tryp-
tophan (TRP), lysine (LYS), histidine (HIS) and arginine 
(ARG) decreased. Figure 1 shows changes with time for 
72hr of concentrations of ALA, ASP and GLN as respec-
tive examples. Any of the amino acids showed higher 
concentration at 72hr in the sample treated with ADM than 
that not treated (Fig. 2) 
2) Free Amino Acids in Cells 
The concentration of each amino acid at 72hr was com-
pared between samples treated with ADM and not treated.
Fig. 1. Changes of concentrations of free amino acids in medium. 0, control. ®, treatment with ADM. (n = 3, Bars indicate mean + 
SD)
Fig. 2. Concentrations of free amino acids in medium at 72 hour. (n = 3, Bars indicate mean ± SD)
All the 22 amino acids other than CYS and ARG showed 
higher concentration in the sample treated with ADM. 
Furthermore, SER, ASN, GLN, TRP and ALA, among 
others, showed twice or more increase by the treatment 
with ADM as compared with the non-treated control (Fig. 
3). 
  Concentrations of amino acids at 72hr in the cells treated 
with ADM were compared with those in M phase cells 
treated with Colcemide to evaluate the effect of cell cycle. 
GLN, ALA and ARG showed higher concentrations in 
ADM-treated cells than Colcemide-treated ones (Table 1). 
3) Growth Curve of HeLa Cells 
The amino acids that decreased in the culture medium of 
HeLa cells treated with ADM and more increased in the 
cells treated with ADM than in M phase cells were GLN 
and ARG. Therefore, the growth curve of HeLa cells in 
RPMI1640 medium of GLN-deficiency was investigated. A 
marked cytocidal effect was obtained at 72 to 96hr by 
adding ADM to medium of GLN-deficiency. The effect of 
this treatment was greater than the inhibitory effects of 
RPMI1640 medium of GLN-deficiency alone and 
RPMI1640 medium containing ADM on the growth of 
HeLa cells (Fig. 4).
Fig. 3. Concentrations of free amino acids in cells at 72 hour. (n = 3, Bars indicate mean ± SD)
Table 1. Comparison of free amino acids in cells treated with 
Colcemide and Adriamycin. (n = 3, Figures indicate mean ± SD)
Amino acid Colcemide (,umol/g) Adriamycin (,amol/g) 
   TAU 0.08 ± 0.01 0.08 ± 0.02 
   ASP 1.00 ± 0.21 0.68 ± 0.04 
   THR 0.11 ± 0.03 0.07 ±0.01 
   SER 0.08 ± 0.01 0.08 ± 0.03 
   ASN 0.12 ± 0.04 0.03 ± 0.00 
   GLU 1.16 ± 0.06 1.06 ± 0.15 
   GLN t 0.01 ± 0.00 
   PRO 0.35 ± 0.02 0.19 ± 0.01 
   GLY 0.40 ± 0.04 0.32 ± 0.02 
   ALA 0.19 ± 0.01 0.22 ± 0.02 
   CIT 0.02 ± 0.01 0.02 ± 0.00 
   VAL 0.12 ± 0.02 0.07 ± 0.01 
  CYS t t 
   MET 0.03 ± 0.01 0.01 ±0.00 
   ILE 0.17 ± 0.03 0.06 ± 0.01 
   LEU 0.19 ± 0.02 0.10 ± 0.06 
   TYR 0.08 ± 0.01 0.04 ± 0.00 
   PHE 0.07 ± 0.02 0.04 +-0.00 
   ORN 0.25 ± 0.07 0.05 ± 0.01 
   TRP 0.02 ± 0.00 0.01 ± 0.00 
   LYS 0.10 ± 0.01 0.01 ±0.00 
   HIS 0.07 ± 0.01 0.02 ± 0.01 
   ARG t 0.01 ± 0.00 
t: trace Fig. 4. Growth curve of HeLa cells in each condition.
Discussion 
In the present study, depletion of which amino acid in 
imbalanced amino acid solution should most effectively 
damage tumor cells when combined with chemotherapy or 
when used after chemotherapy was investigated in vitro. 
Thirteen amino acids out of 24 decreased in the culture 
medium of HeLa cells and increased in cells by the treat-
ment with ADM. There are two possibilities for the 13 
amino acids in the situation which cell proliferation stopped 
by the treatment with ADM: One possibility is that they 
furiously participate in some intracellular metabolism and 
the other is that the half life of disintegration of these 
amino acids is extended. 
 Attention should also be given to the fact that ADM has 
an effect of cell accumulation in G2M phase on cell cycle. 
This raises concern that the present study might have 
evaluated only concentrations of free amino acids in G2M 
cells. Concentrations of free amino acids in ADM-treated 
M phase cells were compared with those treated with 
Colcemide to exclude the possibility. In this comparison, 
amino acids that showed higher concentrations by the 
treatment with ADM than with Colcemide were GLN, ALA 
and ARG. GLN and ARG, above all, were found to have 
decreased in medium by the treatment with ADM. On the 
basis of the finding, a marked cytocidal effect was obtained 
in the medium deficient in GLN, which is a non-essential 
amino acid, combined with ADM. This suggests an import-
nat role of GLN in the intracellular metabolism of HeLa 
cells damaged by ADM. 
  Report on the relation between GLN metabolism and 
growth kinetics of tumor cells''' indicate that a large part of 
energy production of HeLa cells depends on GLN, and 
GLN in HeLa cells, in the presence of fructose, supplies 
about 95% of the whole energy. HeLa cell, as suggested by 
these reports, may be an exceptional cell. Woolly et al 6) 
report that single-amino acid depletion affected cell growth 
kinetics potently in the order of GLN, TRP and ASN. 
  Dranoff et al $' report on their experiment with the cell 
lines obtained from anaplastic glioma and medulloblastoma 
that anaplastic glioma failed to proliferate without the 
supply of GLN, but medulloblastoma well proliferated. As 
a result, they point out that the dependency on GLN differs 
between cell lines. Matsuno et al 9' and many investi-
gators,"' 10-13) on the other hand, have concluded in their 
reports about the GLN metabolism in tumor cells that GLN 
may be an essential amino acid for highly GLN-requiring 
tumor cells based on their observations: 1) Many tumor 
cells tend to need much GLN for growth and 2) GLN 
cannot be synthesized sufficiently in tumor cells because 
they are with poorly active GLN synthetase. 
 The amino acid imbalance therapy is clinically applied in 
some hospitals as an adjunct to cancer chemotherapy. It 
might, however, perform metabolism of GLN on the liver 
or other important organs and furthermore GLN would be
extensively distributed in the body,` `') making its clinical 
application very difficult. This might be a reason why 
GLN-depleted amino acid imbalance therapy is not so 
common. On the other hand, Wiss et al 16) have reported that 
responses were obtained in 10 out of 22 patients of colon 
cancer who received a regimen with Azotomycin, an 
L-glutamine antagonist, combined with 5-fluorouracil. L-
glutamine antagonists, as suggested by this report, can 
inhibit glutamine metabolism and are well-available for 
clinical application. It would be more practical if amino 
acids' concentrations could be locally controlled. One 
expectable administration method for that purpose would 
be to use an intraarterial catheter or other devices to 
administer antitumor agents and L-glutamine antagonists 
selectively to the tumor-controlling artery.
References 
 1) Allan, J. D., Ireland, J. T., Milner, J. and Moss, A. D.: Treatment of 
   leukemia by amino acid imbalance. Lancet 1:302-303, 1965. 
 2) Goseki, N., Onodera, S. and Menjo, M.: Clinical study of amino acid 
    imbalance as an adjunct to cancer therapy. J. Jpn. Soc. Cancer Ther. 
   17:1908-1916, 1982. 
 3) Goseki, N., Mori, S., Habu, H. and Menjo, M.: Effect of intravenous 
   methionine-free hyperalimentation combined with anticancer drugs 
   (RT-Therapy) on adenocarcinoma of gastrointestinal tract. JJPEN 
   2:265-271, 1980. 
 4) Tagawa, Y.: Relationship between G2 accumulation and RNA content 
   of PC1 cells in unbalanced growth induced by antitumor agents. J. 
    Jpn. Soc. Cancer. Ther. 22:590-602, 1987. 
 5) Maehara, H., Ania, H., Kusumoto, H. and Sugimachi, K.: Effect of 
   antitumor drug on protein synthesis chinese hamster V79 cells. Pro-
   ceedings of the 45th Annual Meeting of the Japanese Cancer Associ-
   ation, Sapporo, Hokkaido (Abstr.) 1110, 307, 1986. 
 6) Woolly, P. V., Colt, R. and Magno, M.: Possible L-glutamine antago-
   nists in the treatment of gastrointestinal cancer. Cancer Treatment 
   Reports 63:1039-1040, 1979. 
 7) Reitzer, L. J., Wice, B. M. and Kennell, D.: Evidence that glutamine, 
   no sugar, is the major energy source for cultured HeLa cells. J. Biol. 
   Chemo. 254:2669-2679, 1979. 
 8) Dranoff, G., Elion, G. B., Friedman, H. S., Campbell, G. L. and 
   Bigner, D. D.: Influence of glutamine on growth human glioma and 
   medulloblastoma in cultures. Cancer Res. 45:4077-4081, 1985. 
 9) Matsuno, T. and Satoh, T.: Glutamine metabolism in the avian host 
   bearing transplantable hepatomatous growth induced by MC-29 virus. 
   Inst. J. Biochem. 18:187-189, 1986. 
10) Sebot, J. S. and Weber, G.: Negative correlation of L-glutamine 
   concentration with proliferation rate in rat hepatoma. Lite Sci. 
   34:341-306, 1984. 
11) Pine, M. J.: Depletions in glutamine, asparagine, isoleucine and 
   ornithine pools of rodent and human tumor. Proceedings of the 74th 
   Annual Meeting of the American Association for Cancer Research, 
   San Diego, CA (Abstr.) 24, 47, 1983. 
12) Pilkington, G. J. and Lantos, P. L.: The role of glutamine synthetase in 
   the diagnosis of cerebral tumors. Neuropathol. Appl. Neurobiol. 
   8:227-236, 1982. 
13) Abou-Khalil, W. H., Yunis, A. A. and Abou-Khalil, S.: Prominent 
   glutamine oxidation activity in mitochondria of hematopoietic tumors. 
   Cancer Res. 43:1990-1993, 1983. 
14) Yoshimura, K. and Mochizuki, H.: Infusion of amino acids supplem-
   ented with glutamine a key amino acids gut mucosal metabolism in 
   stressed cases. Igalu no Ayumi 149:385-392, 1989. 
15) Ishikawa, E.: Dynamic aspects of free amino acids in the blood. Eiyo 
   to shokuryou 30:241-248, 1977. 
16) Wiss, A. J. and Mastranglo, M. J.: Phase I study of a combination of 
   azotomycine (NCC-19893) in malignant disease. Cancer Chemother. 
   Res. 54:109-110, 1970.
